These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 30236877)

  • 1. Pharmacogenomics of Alzheimer's and Parkinson's diseases.
    Cacabelos R
    Neurosci Lett; 2020 May; 726():133807. PubMed ID: 30236877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease pharmacogenomics: new findings and perspectives.
    Schumacher-Schuh AF; Rieder CR; Hutz MH
    Pharmacogenomics; 2014 Jun; 15(9):1253-71. PubMed ID: 25141900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.
    Cacabelos R
    Mol Diagn Ther; 2007; 11(6):385-405. PubMed ID: 18078356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenomics and therapeutic prospects in Alzheimer's disease.
    Cacabelos R
    Expert Opin Pharmacother; 2005 Oct; 6(12):1967-87. PubMed ID: 16197352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development.
    Cacabelos R; Naidoo V; Martínez-Iglesias O; Corzo L; Cacabelos N; Pego R; Carril JC
    Methods Mol Biol; 2022; 2547():275-387. PubMed ID: 36068470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Parkinson's Disease Pharmacogenomics: Is There Time for Translation into the Clinics?
    Vuletić V; Rački V; Papić E; Peterlin B
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches.
    Cruz-Vicente P; Passarinha LA; Silvestre S; Gallardo E
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33920326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular genetics of Alzheimer's disease and aging.
    Cacabelos R; Fernandez-Novoa L; Lombardi V; Kubota Y; Takeda M
    Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insights in pharmacogenetics of drug response in Parkinson's disease.
    Arbouw ME; Guchelaar HJ; Egberts TC
    Pharmacogenomics; 2010 Feb; 11(2):127-9. PubMed ID: 20136351
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics-a New Frontier for Individualized Treatment of Parkinson's Disease.
    Liu JS; Chen Y; Shi DD; Zhang BR; Pu JL
    Curr Neuropharmacol; 2023; 21(3):536-546. PubMed ID: 36582064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic considerations in the treatment of Alzheimer's disease.
    Cacabelos R; Torrellas C; Teijido O; Carril JC
    Pharmacogenomics; 2016 Jun; 17(9):1041-74. PubMed ID: 27291247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics of Alzheimer's disease: novel therapeutic strategies for drug development.
    Cacabelos R; Cacabelos P; Torrellas C; Tellado I; Carril JC
    Methods Mol Biol; 2014; 1175():323-556. PubMed ID: 25150875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics of Aging and Alzheimer's Disease: Implications for Pharmacogenomics and Drug Response.
    Cacabelos R; Torrellas C
    Int J Mol Sci; 2015 Dec; 16(12):30483-543. PubMed ID: 26703582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics in Parkinson's disease treatment].
    Białecka M; Kłodowska-Duda G; Kurzawski M; Droździk M
    Neurol Neurochir Pol; 2008; 42(2):131-8. PubMed ID: 18512170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary study to identify CXCR4 inhibitors as potential therapeutic agents for Alzheimer's and Parkinson's diseases.
    Tripathi R; Kumar P
    Integr Biol (Camb); 2023 Apr; 15():. PubMed ID: 37635325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
    Arbouw ME; van Vugt JP; Egberts TC; Guchelaar HJ
    Pharmacogenomics; 2007 Feb; 8(2):159-76. PubMed ID: 17286539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of pharmacogenetics in Parkinson's disease treatment.
    Hutz MH; Rieder CR
    Pharmacogenomics; 2018 Feb; 19(3):171-174. PubMed ID: 29191064
    [No Abstract]   [Full Text] [Related]  

  • 20. The applications of pharmacogenomics to neurological disorders.
    Gilman C; McSweeney C; Mao Y
    Curr Mol Med; 2014; 14(7):880-90. PubMed ID: 25109797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.